Last reviewed 2026-04-23 · How we verify

CHOP Plus Lanzoprazole

Sherief Abd-Elsalam · Phase 3 active Small molecule

CHOP Plus Lanzoprazole is a Combination chemotherapy regimen with proton pump inhibitor Small molecule drug developed by Sherief Abd-Elsalam. It is currently in Phase 3 development for Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori, Lymphoma with gastric involvement requiring gastroprotection. Also known as: CHOP Plus Lanzoprazole 60.

CHOP Plus Lansoprazole combines chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with a proton pump inhibitor to treat Helicobacter pylori infection and gastric conditions.

CHOP Plus Lansoprazole combines chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with a proton pump inhibitor to treat Helicobacter pylori infection and gastric conditions. Used for Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori, Lymphoma with gastric involvement requiring gastroprotection.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CHOP Plus Lanzoprazole
Also known as	CHOP Plus Lanzoprazole 60
Sponsor	Sherief Abd-Elsalam
Drug class	Combination chemotherapy regimen with proton pump inhibitor
Target	H+/K+-ATPase (lansoprazole component); multiple targets (CHOP chemotherapy)
Modality	Small molecule
Therapeutic area	Oncology; Gastroenterology
Phase	Phase 3

Mechanism of action

CHOP is a standard chemotherapy regimen used primarily in lymphoma treatment, while lansoprazole reduces gastric acid production by inhibiting the H+/K+-ATPase pump. The combination may be used to manage H. pylori-associated gastric lymphoma or to provide gastroprotection during chemotherapy. Lansoprazole helps prevent chemotherapy-induced gastrointestinal toxicity and treats underlying acid-related disease.

Approved indications

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori
Lymphoma with gastric involvement requiring gastroprotection

Common side effects

Nausea and vomiting
Myelosuppression
Headache
Diarrhea
Abdominal pain

Key clinical trials

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CHOP Plus Lanzoprazole CI brief — competitive landscape report
CHOP Plus Lanzoprazole updates RSS · CI watch RSS
Sherief Abd-Elsalam portfolio CI

Frequently asked questions about CHOP Plus Lanzoprazole

What is CHOP Plus Lanzoprazole?

CHOP Plus Lanzoprazole is a Combination chemotherapy regimen with proton pump inhibitor drug developed by Sherief Abd-Elsalam, indicated for Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori, Lymphoma with gastric involvement requiring gastroprotection.

How does CHOP Plus Lanzoprazole work?

CHOP Plus Lansoprazole combines chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) with a proton pump inhibitor to treat Helicobacter pylori infection and gastric conditions.

What is CHOP Plus Lanzoprazole used for?

CHOP Plus Lanzoprazole is indicated for Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori, Lymphoma with gastric involvement requiring gastroprotection.

Who makes CHOP Plus Lanzoprazole?

CHOP Plus Lanzoprazole is developed by Sherief Abd-Elsalam (see full Sherief Abd-Elsalam pipeline at /company/sherief-abd-elsalam).

Is CHOP Plus Lanzoprazole also known as anything else?

CHOP Plus Lanzoprazole is also known as CHOP Plus Lanzoprazole 60.

What drug class is CHOP Plus Lanzoprazole in?

CHOP Plus Lanzoprazole belongs to the Combination chemotherapy regimen with proton pump inhibitor class. See all Combination chemotherapy regimen with proton pump inhibitor drugs at /class/combination-chemotherapy-regimen-with-proton-pump-inhibitor.

What development phase is CHOP Plus Lanzoprazole in?

CHOP Plus Lanzoprazole is in Phase 3.

What are the side effects of CHOP Plus Lanzoprazole?

Common side effects of CHOP Plus Lanzoprazole include Nausea and vomiting, Myelosuppression, Headache, Diarrhea, Abdominal pain.

What does CHOP Plus Lanzoprazole target?

CHOP Plus Lanzoprazole targets H+/K+-ATPase (lansoprazole component); multiple targets (CHOP chemotherapy) and is a Combination chemotherapy regimen with proton pump inhibitor.

Drug class: All Combination chemotherapy regimen with proton pump inhibitor drugs
Target: All drugs targeting H+/K+-ATPase (lansoprazole component); multiple targets (CHOP chemotherapy)
Manufacturer: Sherief Abd-Elsalam — full pipeline
Therapeutic area: All drugs in Oncology; Gastroenterology
Indication: Drugs for Gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori
Indication: Drugs for Lymphoma with gastric involvement requiring gastroprotection
Also known as: CHOP Plus Lanzoprazole 60

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing